SCHEMBL8802

SCHEMBL8802

[CH2]C(=O)NN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11332910 0.73
Formaldehyde SCHEMBL28328963 0.70
Hydrazinecarboxamide SCHEMBL1864580 0.70
Hydrazinecarboxamide SCHEMBL27840683 0.70
Hydrazinecarboxamide SCHEMBL10889812 0.70 TSHR (0.83)
Hydrazinecarboxamide SCHEMBL28812032 0.67 TSHR (0.77)
Hydrazinecarboxamide SCHEMBL15393 0.67
SCHEMBL325517 0.67
SCHEMBL7258925 0.67 TSHR (0.54)
SCHEMBL20178517 0.67 NFKB1 (0.54)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 17866 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238282-A1 METHODS OF TREATING CANCER AND ISCHEMIA DISEASES BY INHIBITION AND INTERVENTION OF ATR PROLYL ISOMERIZATION THE UNIVERSITY OF TOLEDO (US) 2024-07-18 US claimed
US-20240216401-A1 COMBINATION THERAPY BY USING AKR1C3-ACTIVATED COMPOUND WITH IMMUNE CHECKPOINT INHIBITOR OBI PHARMA, INC. (TW) 2024-07-04 US claimed
US-20240207433-A1 DRUG CONJUGATES CONTAINING ALPHA-ENOLASE ANTIBODIES AND USES THEREOF HUNILIFE BIOTECHNOLOGY, INC. (TW) 2024-06-27 US claimed
US-11998584-B2 Conjugate of a tubulysin analog with branched linkers HANGZHOU DAC BIOTECH CO., LTD. (CN) 2024-06-04 US claimed
US-11975076-B2 Antibody-drug conjugates comprising branched linkers and methods related thereto LEGOCHEM BIOSCIENCES, INC. (KR) 2024-05-07 US claimed
US-20240131178-A1 ANTIBODY-DRUG CONJUGATE INCLUDING ANTIBODY AGAINST HUMAN CLDN18.2, AND USE THEREOF LEGOCHEM BIOSCIENCES, INC. (KR) 2024-04-25 US claimed
EP-3380124-B1 CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO LEGOCHEM BIOSCIENCES INC (KR) 2024-04-03 EP claimed
CN-117729917-A Combination therapy using AKR1C3 activating compounds and immune checkpoint inhibitors 深圳艾欣达伟医药科技有限公司 2024-03-19 CN claimed
EP-4329745-A1 COMBINATION THERAPY BY USING AKR1C3-ACTIVATED COMPOUND WITH IMMUNE CHECKPOINT INHIBITOR OBI PHARMA, INC. (TW) 2024-03-06 EP claimed
EP-4321180-A1 ANTIBODY-DRUG CONJUGATE INCLUDING ANTIBODY AGAINST HUMAN CLDN18.2, AND USE THEREOF LegoChem Biosciences, Inc. (KR) 2024-02-14 EP claimed
EP-1024799-A1 METHOD FOR TREATING DISEASE-RELATED OR DRUG-INDUCED DYSKINESIAS WARNER-LAMBERT COMPANY (US) 2000-08-09 EP claimed
WO-2000009131-A1 DIAMINOPYRIMIDINES AND COMBINATION THERAPIES EFFECTIVE FOR TREATMENT OF P-GLYCOPROTEIN POSITIVE CANCERS WARNER-LAMBERT COMPANY (US) 2000-02-24 WO claimed
WO-2000000197-A1 4-BENZYL PIPERIDINE ALKYLSULFOXIDE HETEROCYCLES AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 2000-01-06 WO claimed
EP-0869792-A4 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS WARNER LAMBERT CO (US) 1999-09-22 EP claimed
WO-1999021539-A1 METHOD FOR TREATING DISEASE-RELATED OR DRUG-INDUCED DYSKINESIAS WARNER-LAMBERT COMPANY (US) 1999-05-06 WO claimed
EP-0869792-A2 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1998-10-14 EP claimed
WO-1997023216-A1 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1997-07-03 WO claimed
EP-0282547-A4 METHOD FOR CONTROLLING EMESIS CAUSED BY CHEMOTHERAPEUTIC AGENTS AND ANTIEMETIC AGENTS USEFUL THEREIN 1990-11-28 EP claimed
EP-0282547-A1 METHOD FOR CONTROLLING EMESIS CAUSED BY CHEMOTHERAPEUTIC AGENTS AND ANTIEMETIC AGENTS USEFUL THEREIN. ADRIA LAB INC (US) 1988-09-21 EP claimed
WO-1988001866-A1 METHOD FOR CONTROLLING EMESIS CAUSED BY CHEMOTHERAPEUTIC AGENTS AND ANTIEMETIC AGENTS USEFUL THEREIN ADRIA LABORATORIES, INC. (US) 1988-03-24 WO claimed